August 26, 2025 — Leads & Copy — Clearside Biomedical, Inc. (Nasdaq: CLSD) will showcase its suprachoroidal space (SCS) delivery platform and CLS-AX program at the 25th EURETINA Congress in Paris, France, from September 4-7, 2025. Victor Chong, MD, MBA, Chief Medical Officer and EVP, Head of Research and Development will also participate in a panel discussion at the Ophthalmology Futures Retina Forum on September 3, 2025.
Clearside’s platform aims to provide targeted treatment for retinal diseases, including wet AMD and diabetic retinopathy.
Dr. Chong noted that the company has designed a Phase 3 trial in wet AMD in alignment with the U.S. FDA, and a streamlined Phase 2 trial in non-proliferative diabetic retinopathy.
Presentations will include data on suprachoroidally administered CLS-AX in participants with neovascular age-related macular degeneration, a decade-long review of suprachoroidal drug delivery, and suprachoroidal gene therapy for diabetic retinopathy.
Victor Chong, MD, MBA, Chief Medical Officer and EVP, Head of Research and Development
ir@clearsidebio.com
Source: Clearside Biomedical, Inc.
